Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

Entheon Announces Execution of Business Combination Agreement with Nutravisor

ENBI · Price

Executive Summary

  • Entheon Biomedical Corp. entered into a definitive Business Combination Agreement to merge with Nutravisor Inc. via a three‑cornered amalgamation that will result in Entheon being reverse‑taken over by Nutravisor and renamed “STRYK Brands Inc.”
  • The transaction includes a share consolidation (≈ 1 post‑Consolidation Entheon Share for every 6.93 pre‑Consolidation shares) and an exchange ratio of 4.2395 post‑Consolidation Entheon Shares per Nutravisor Share, valuing Nutravisor at $40 M and issuing ~53.3 M new Entheon Shares to Nutravisor shareholders.
  • Completion is contingent on a $4–10 M equity financing by Nutravisor, shareholder approvals, CSE listing approval, and other regulatory conditions; trading of Entheon shares is currently halted.

Key Details

  • Transaction Structure
  • Three‑cornered amalgamation under the Ontario Business Corporations Act involving Entheon, its wholly‑owned subsidiary (Subco), and Nutravisor.
  • Post‑closing, Nutravisor will become a wholly‑owned subsidiary of Entheon; Entheon will adopt Nutravisor’s business and rename to “STRYK Brands Inc.” (or similar).

  • Share Consolidation

  • One post‑Consolidation Entheon Share for every 6.93 pre‑Consolidation shares (subject to adjustment).

  • Exchange Ratio & Valuation

  • Each Nutravisor shareholder receives 4.2395 post‑Consolidation Entheon Shares per Nutravisor Share.
  • Nutravisor valued at $40 M; ~53,333,333 post‑Consolidation Entheon Shares to be issued (excluding shares for financing).

  • Financing Requirements

  • Nutravisor to complete equity financings (“Nutravisor Financings”) raising between $4 M and $10 M via a private placement of Nutravisor Shares and concurrent subscription receipts, priced per CSE policies.

  • Lock‑up & Finder’s Fee

  • Voluntary lock‑up on Entheon Shares issued to Nutravisor shareholders: 25% released six months after closing, with additional 25% releases every six months thereafter.
  • $500,000 finder’s fee payable to ALOE Finance Inc., settled by issuance of Resulting Issuer Shares at a deemed price of $0.75 per share.

  • Break‑Fee

  • Mutual break fee of $100,000 if either party terminates the transaction under specified circumstances.

  • Regulatory & Shareholder Approvals

  • Required CSE conditional approval for listing of resulting issuer’s shares.
  • Entheon to file Form 2A Listing Statement with the CSE.
  • Annual General and Special Shareholder Meeting scheduled for March 2026 to approve the transaction, consolidation, name change, and director appointments.

  • Management & Governance

  • Post‑closing board expected to have at least three directors, led by Max Krangle as CEO and Director; additional directors to be nominated by Nutravisor.

  • Trading Halt

  • Entheon’s common shares are halted pending completion of required documentation and CSE approval.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Entheon Biomedical Corp.